On a mission to develop safe and effective treatments for our pet family members
Therapeutic Areas
ATOPIC DERMATITIS
​
A chronic severe skin condition that leads to itching for millions of dogs and cats
OSTEOARTHRITIS​
​
Chronic joint pain that results in lameness for millions of horses and dogs
Recent News
4/2/2022
Data read out for the pilot study for ALX 101 at North Carolina State University demonstrates both efficacy of the product and a positive consumer experience
​
1/25/2021
First patient in the pilot study for ALX 101 at North Carolina State University enrolled.
​
5/28/2020
Aniluxx Biotechnology is invited to participate in MassChallenge Houston
​
3/25/2020
FDA accepts the INAD submission for ALX 101, an investigational topical therapy for canine allergic dermatitis
​
Aniluxx to Present at the North Carolina Biotechnology Center Symposium on Itch
​
1/08/2020
Aniluxx selected to Present at the North Carolina Center for Entrepreneurial Development Life Sciences Conference
​
12/20/2019
Aniluxx Files SEC Form D Reporting Seed Stage Investment